Key information

🔎 Fund Overview

Prime Medicine, Inc. is a United States-based biotechnology company. The Company is engaged in multiple drug discovery programs that target liver, eye, ex-vivo hematopoietic stem cell and neuro-muscular indications. The Company's Prime Editing, a transformative technology that addressed the cause of genetic disease. The Company's collaborative approach help fight disease and accelerating the development of Prime Editing to deliver therapies for patients. Its Prime Editing is used to modify gene-regulatory sequences. These edits can be made in therapeutically relevant cells and organs, including specialized terminally differentiated cells. Its Prime Editing acts as a Deoxyribonucleic acid (DNA) word processor, with the power to search and replace genetic sequences at their exact location in the genome, all without making double-strand breaks in DNA.